Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Weill Cornell Medicine

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
781
Shown on this page
12
Current sort
Recently updated
Campus scope
Weill Cornell Medicine, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Weill Cornell Medicine, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 685–696 of 781 matching trials with a site at Weill Cornell Medicine, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Not applicable Interventional

Diffusion MRI for Head and Neck Cancer

NCT04251481
Site status not listed — check the official record
Conditions
Head Cancer Neck
Interventions
PET/MRI with FDG, MRI scan without contrast, MRI with gadolinium
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
New York, New York
Recruiting Phase 4 Interventional Accepts healthy volunteers

Split Face Study of the Duration of Local Anesthetics - Fourth Arm

NCT06694714
Status at this site: Recruiting
Conditions
Anesthesia, Local
Interventions
0.5 ml lidocaine + epinephrine 1:100,000, 1.0 ml lidocaine + epinephrine 1:100,000
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Recruiting No phase listed Observational Accepts healthy volunteers

Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors

NCT05164744
Status at this site: Recruiting
Conditions
COVID-19 Pneumonia, COVID-19, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome, COVID-19 Lower Respiratory Infection, COVID-19 Acute Bronchitis, Coronavirus Disease 2019
Interventions
Cardiac MRI, Echocardiogram, 6-minute walk test, Questionnaire
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
Brooklyn, New York • New York, New York
Active, not recruiting Early Phase 1 Interventional

Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy

NCT04937062
Site status not listed — check the official record
Conditions
STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder, Developmental and Epileptic Encephalopathy
Interventions
Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
0 Months to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Recruiting No phase listed Observational

Fecal Microbiota Transplant National Registry

NCT03325855
Status at this site: Recruiting
Conditions
Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
Interventions
None - Observational
Other
Lead sponsor
American Gastroenterological Association
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
52
States / cities
Phoenix, Arizona • Los Angeles, California • Redwood City, California + 39 more
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

NCT03398135
Site status not listed — check the official record
Conditions
Ulcerative Colitis (UC)
Interventions
risankizumab, placebo for risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
78
States / cities
Coronado, California • Irvine, California • La Jolla, California + 60 more
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

NCT06577090
Site status not listed — check the official record
Conditions
Obesity
Interventions
Nimacimab injection, Nimacimab placebo injection, semaglutide injection, Nimacimab 300 mg injection
Biological · Combination Product
Lead sponsor
Skye Bioscience, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Anniston, Alabama • Walnut Creek, California • Waterbury, Connecticut + 13 more
Active, not recruiting Not applicable Interventional

Living Healthy for Moms RCT

NCT06666400
Site status not listed — check the official record
Conditions
Postpartum Depression (PPD), Cardiac Event
Interventions
LHMoms Intervention, No intervention
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Brooklyn, New York • Jamaica, New York • New York, New York
Active, not recruiting Not applicable Interventional Results available

PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis

NCT02675114
Site status not listed — check the official record
Conditions
Aortic Stenosis
Interventions
SAVR, SAPIEN 3 THV
Procedure · Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Burlingame, California + 59 more
Active, not recruiting No phase listed Observational

Liver Cirrhosis Network Cohort Study

NCT05740358
Site status not listed — check the official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Active, not recruiting Phase 3 Interventional Results available

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

NCT04647526
Site status not listed — check the official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
[Lu-177]-PNT2002, Abiraterone, Enzalutamide
Drug
Lead sponsor
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
33
States / cities
Tucson, Arizona • Los Angeles, California • Newport Beach, California + 24 more
Recruiting No phase listed Observational

Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs

NCT02493478
Status at this site: Suspended
Conditions
Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
150,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 50 more

About this Weill Cornell Medicine institution page

What this page lists
ClinicalTrials.gov records that list Weill Cornell Medicine in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.